- Szerzők: Laniece Delaunay C., Melo A., Maurel M., Mazagatos C., Goerlitz L., O’Donnell J., Oroszi B., Sève N., Rodrigues A.P., Martínez-Baz I., Meijer A., Mlinarić I., Latorre-Margalef N., Lazăr M., Pérez-Gimeno G., Dürrwald R., Bennett C., Túri G., Rameix-Welti M
- Megjelenés: 2024, Vaccine
- URL: https://www.sciencedirect.com/science/article/pii/S0264410X24006443?via%3Dihub
- MTMT azonosító: 34985433
Absztrakt: In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a test-negative case–control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26–53 %) overall, 48 % (95 % CI: 31–61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3–49 %) at 6–14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies.